Rocha-Muñoz Alberto D, González-López Laura, Peguero-Gómez Rebeca, Aguilar-Chávez Erika A, Villa-Manzano Alberto I, Corona-Sánchez Esther, Galván-Méndez Silvia, Presiado-Sánchez Carmen, Vázquez-Jiménez José C, Riebeling Carlos, Salazar-Páramo Mario, Gámez-Nava Jorge I, Nava Arnulfo
Departamento de Medicina Interna-Reumatología, Hospital General Regional 110, IMSS, Guadalajara, Jalisco, México.
Rev Alerg Mex. 2009 Jul-Aug;56(4):103-7.
To evaluate sera titers for antibodies anti-cyclic citrullinated peptide and their correlation against sera levels of anti-topoisomerase I and anti-centromere antibodies in Mexican patients with systemic sclerosis.
Consecutive outpatients with systemic sclerosis who attending to rheumatology clinic at a second level hospital facility. The antibodies anti-cyclic citrullinated peptide, anti-topoisomerase I and anti-centromere were determined by enzymatic immunoassay (ELISA).
Spearman for correlation between numerical variables with nonparametric distribution. Fisher exact test or chi2 to compare proportions and Student t test for dimensional variables.
Thirty female patients were included; aged 53 +/- 13, the disease duration at the time of the study was 10 +/- 9. Twenty-three patients (77%) exhibited diffuse disease. Anti-centromere, anti-topoisomerase I, and anti-cyclic citrullinated peptide were detected in nine, nine and three patients respectively. The correlation analysis showed the independence of autoantibodies anti-centromere and anti-topoisomerase I with respect to the levels of anti-cyclic citrullinated peptide.
This study confirms the low frequency of anti-cyclic citrullinated peptide antibodies in patients with systemic sclerosis. A lack of correlation between autoantibodies considered as "mutually excluded" anti-topoisomerase I and anti-centromere, indicating that the analysis of the relevance for anti-cyclic citrullinated peptide in systemic sclerosis must include other clinical and serological variables.
评估墨西哥系统性硬化症患者中抗环瓜氨酸肽抗体的血清滴度及其与抗拓扑异构酶I和抗着丝点抗体血清水平的相关性。
连续纳入在二级医院风湿科门诊就诊的系统性硬化症门诊患者。采用酶免疫测定法（ELISA）检测抗环瓜氨酸肽、抗拓扑异构酶I和抗着丝点抗体。
采用Spearman法分析非参数分布的数值变量之间的相关性。采用Fisher确切概率法或卡方检验比较比例，采用Student t检验分析维度变量。
纳入30例女性患者；年龄53±13岁，研究时疾病病程为10±9年。23例患者（77%）表现为弥漫性疾病。分别在9例、9例和3例患者中检测到抗着丝点抗体、抗拓扑异构酶I和抗环瓜氨酸肽抗体。相关性分析显示抗着丝点抗体和抗拓扑异构酶I自身抗体水平与抗环瓜氨酸肽水平无关。
本研究证实系统性硬化症患者中抗环瓜氨酸肽抗体的频率较低。被认为“相互排斥”的抗拓扑异构酶I和抗着丝点自身抗体之间缺乏相关性，这表明在系统性硬化症中分析抗环瓜氨酸肽的相关性时必须纳入其他临床和血清学变量。
